In the ABSORB Cohort B trial patients with non-complex de novo lesions were treated with second iteration bioresobable vascular scaffold (BVS). MSCT angiography was performed as an optional investigation at 18 months; patients were reconsented for a second investigation at 72 months. MSCT data were analysed at independent core laboratories for quantitative analysis of lumen dimensions and for calculation of fractional flow reserve derived from computed tomography (FFR CT ). From the overall Cohort B (101 patients), 53 patients underwent MSCT imaging at 72 months. The MACE rate was 1.9% (1/53). At 72 months, the median minimal lumen area (MLA) was 4.05 mm 2 
Introduction
Despite the inherent risk of caging the coronary artery with metallic stent, percutaneous coronary interventions (PCI) have been demonstrated to be of clinical benefit in patients with ischaemic coronary artery disease. 1 However, the concept of a fully resorbable technology has attracted the interventional community since the early days of PCI. The bioresorbable vascular scaffolds have been developed and introduced into clinical practice. 2 The temporal scaffolding of the coronary artery has the advantage of preventing acute vessel closure after balloon dilatation, delivering anti-restenotic drugs to the vessel wall to control the process of restenosis while restoring the natural integrity of the vessel. 3 Moreover the polymeric backbone of the scaffold is radio-lucent and does not interfere with the assessment of the opacified lumen using noninvasive multislice computed tomography (MSCT) angiography, providing an alternative to invasive angiography for the follow-up of the patients treated with PCI. The second iteration of the fully resorbable everolimus-eluting scaffold was tested in the ABSORB (ABSORB Clinical Investigation, Cohort B Everolimus Eluting Coronary Stent System Clinical Investigation) trial. (Study Sponsor Abbott Vascular). Patients with non-complex de novo coronary artery lesion were included and studied with multimodality imaging at short, mid, and long-term after implantation (i.e., from 6 months to 60 months). Invasive findings with angiography, intravascular ultrasound (IVUS), virtual histology (VH) and optical coherence tomography (OCT) showed that bioresorption of polymeric struts occurs at 3 years and is associated with late lumen enlargement, plaque, and media reduction, restoration of vasomotion and cyclic strain. 4 In addition, mid-term MSCT evaluation (i.e. 18 months) was shown to be feasible with a scaffold patency observed in 91% of the cases (n = 67); however, long-term non-invasive MSCT follow-up remains to be documented. Computed tomography technology has vastly improved over the past decades. The spatial resolution achieved by the latest generation CT scanners has been shown to provide an accurate assessment of the coronary artery lumen. Furthermore, physiological parameters such as fractional flow reserve derived from computed tomography (FFR CT ) can also be computed using computational fluid dynamics in a 3-D coronary model thereby providing additional information to the purely anatomical evaluation. 5 We sought to evaluate the angiographic and functional outcomes after the treatment of obstructive coronary artery disease with the second iteration of the bioresorbable polymeric everolimus-eluting scaffold by means of serial (18 and 72 months) non-invasive MSCT coronary angiographic plus functional FFR CT assessment.
Methods

Study design
The design of this study has been previously reported. 6 Briefly, this was a single-arm, prospective, open-label, efficacy, and safety study. One hundred and one patients were enrolled at 12 centres between March and November 2009. The overall cohort (B) was subdivided into two groups of patients: the first group (B1) underwent invasive imaging with quantitative coronary angiography, IVUS grayscale, VH and OCT at 6, 24, and 60 months, whereas the second group (B2) underwent invasive imaging at 12, 36, and 60 months; both groups underwent non-invasive cardiac MSCT angiography at 18 months. Before the end of the 5-year follow-up, the protocol was amended to allow the patients who had undergone a MSCT scan as an optional investigation at 18 months to be re-consented to undergo a second MSCT scan at 72 months. From the overall cohort of 101 patients, 80 patients were eligible for reconsent (reasons for not being approached for reconsent (n = 21) are shown in Supplementary data online, Table S1 appendix). Fifty-three patients were consented, 23 refused, 4 could not be reached.
Study device and procedure
The bioresorbable vascular scaffold (BVS) 1.1 balloon-expandable device consists of a polymer backbone of poly-L-lactide (PLLA) coated with a thin layer of a 1:1 mixture of poly(L-lactide-co-D,L-lactide) (PDLLA) polymer and the antiproliferative drug everolimus containing 100 lg everolimus/cm 2 scaffold. The implant is radiolucent but has two platinum markers of 244 lm at each end that allows easy visualization on MSCT and other imaging modalities. PDLLA allows controlled release of the everolimus so that 80% has been eluted by 30 days. Both PLLA and PDLLA are fully resorbable. 7 The scaffolding procedure has been previously described. Briefly, target lesions were treated using standard interventional techniques with mandatory predilatation. Bailout stenting with a Xience-V drug-eluting stent for edge dissection and insufficient coverage of the lesion was recommended if needed. Treatment with aspirin was started at least 24 h before the procedure and was followed by lifelong aspirin treatment according to guidelines of the European Society of Cardiology/American Heart Association/American College of Cardiology. A loading dose of 300 mg clopidogrel was administered before the procedure, followed by 75 mg daily for a minimum of 6 months. 8, 9 MSCT angiography
Cardiac MSCT angiography was performed at 18 months and 72 months with the use of a 64-slice computed tomography technology or beyond (Supplementary data online, Table S2 appendix). Standard acquisition techniques were used, which included the use of nitrates prior to image acquisition and beta-blockers in patients with a fast heart rate (> 65 bpm), tube settings depending on patient body mass index (80-140 kV), and axial scan protocols for patients with lower heart rates to reduce radiation doses, all at the discretion of the individual sites. Images were reconstructed using thin slices (0.5-0.67 mm) and medium smooth reconstruction filters in different phases. All data were stored on a DVD for core laboratory evaluation.
MSCT analysis
Data from MSCT was analysed off-line by an independent Corelab (Cardalysis BV, Rotterdam, The Netherlands) using a validated cardiovascular analysis package (Circulation, Siemens AG, Forchheim, Germany).
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Vessel cross-sections were reconstructed at approximately 1 mm longitudinal increments, extending 5 mm beyond the device, using the remaining platinum scaffold indicators as landmarks. Automatic lumen segmentation of the vessel lumen, with manual correction was performed to measure the lumen area. The outer vessel borders were manually traced to approximate the vessel size, using a window display setting: level, 750 Hounsfield units; width, 250 Hounsfield units, the window level was adjusted if necessary. The mean, minimal lumen area (MLA), and maximum lumen areas were determined for each scaffold. The reference lumen area was calculated as the average between the mean vessel area proximal and distal to the scaffolded segments. The luminal percentage percentage area stenosis was calculated as the difference between the MLA and the reference as a percentage of the reference. A significant area of stenosis was defined as > _75%, which approximates 50% diameter stenosis. Mean plaque burden (PB) in the scaffolded region was defined as mean vessel area minus mean lumen area divided by mean vessel area. Plaque composition was qualitatively assessed for the presence of noncalcified plaque, calcified plaque and mixed plaque at each cross-section. [11] [12] [13] The percentage of cross sections of each plaque type was calculated as a number of cross sections with the plaque type divided by the total number of cross sections analysed in the scaffolded segment.
FFR CT analysis
The FFR CT was performed by an independent core laboratory at HeartFlow, Inc. (Redwood City, California, USA). The detailed methodology is described elsewhere. 14 Using the most recent generation of FFR CT analysis software, for each patient a quantitative 3-D anatomic model of the aortic root and epicardial coronary arteries was generated from coronary MSCT images for each patient. 15 Since the new software iteration enables more accurate FFR CT analysis and higher acceptance rate, the 18-month data was re-analysed by this software. In addition, any patient with a paired MSCT investigation that was analysed originally at 18 months was re-analysed using the new version of the FFR CT software. Coronary blood flow and pressure were computed under conditions simulating maximal hyperaemia. Blood was assumed to be a Newtonian fluid. The FFR CT results are presented as FFR CT distal to the scaffold and FFR CT gradient, defined as the difference between the FFR CT distal and proximal to the scaffold.
Definitions
The composite clinical endpoint is cardiac death, MI classified as Q-wave and non-Q-wave MI, and ischaemia-driven (ID) target lesion revascularization (TLR). ID TLR implies revascularization at the target lesion, irrespective of the time window for angiographic control at 6 months or 2 years, associated with: (i) a positive functional ischaemia study; (ii) ischaemic symptoms and angiographic minimal lumen diameter stenosis > _ 50% by core laboratory quantitative coronary angiography (QCA); or (iii) revascularization of a target lesion with a diameter stenosis > _ 70% by core laboratory QCA without either ischaemic symptoms or a positive functional study. For a diagnosis of non-Q wave MI, elevation of creatine kinase levels two times the upper limit of normal with increased creatine kinase myocardial band was required. 
Results
Baseline characteristics and clinical follow-up
Overall, 101 patients were included in this study. Baseline demographics and five years clinical outcomes have been previously published ( Table 1) . 4 For the cohort of 53 patients who underwent
MSCT imaging at 72 months, the major adverse cardiac events rate at 5 years was 1.9% (1/53), with a TVF (Cardiac Death, MI, ID-TLR, ID-TVR) rate of 3.8% (2/53). This was attributable to one in-hospital MI and one ID Non-TLR TVR between the second and third year. There were no changes in event rates between the fifth and sixth year. In 11 centres, 72 patients underwent MSCT angiography at 18 months, and at a median of 6.1 years (IQR 6.02-6.23) a second MSCT angiography was performed in 53 patients. At 6 years, quantitative MSCT angiographic analysis was feasible in 46 (87%) cases. No quantitative analysis was possible in three patients due to poor MSCT quality; however, in these cases visual percentage area stenosis < _ 50% was found (Figure 1 
Anatomical changes assess by mulstislice CT angiography
Vascular changes were assessed in 39 paired patients by means of serial MSCT angiography (i.e. 18 months and 72 months; Table 2 ). 
Serial non-invasive fractional flow reserve
Of the 39 patients with paired MSCT analysis, FFR CT computations were feasible in 30 (77%) patients. In nine cases, FFR CT analysis was not possible due to large slice thickness or pixel spacing (n = 4), clipped myocardium (n = 2), motion artefact (n = 1), missing data in the CT image (n = 1) and previous coronary artery bypass graph surgery (n = 1). At 72 months, the FFR CT distal to the scaffold was 0.88 (IQR: 0.82-0.92) which was similar to the distal FFR CT found at 18 months (D = 0.02, P = 0.367). There were two asymptomatic patients with FFR CT < 0.80 with a minimum luminal area < 4.00 mm 2 treated medically and one symptomatic patient in whom an FFR CT of 0.79 with a MLA of 2.3 mm 2 was found; this patient underwent a diagnostic cardiac catheterization and found a severe lesion distal to the scaffold with a positive invasive FFR, and consequently underwent ID-non-TLR-TVR-PCI. The scaffold gradient at 72 months was -0.035 (IQR: -0.053 to -0.010) with a delta scaffold gradient of 0 (-0.013-0.010) between time points ( Figure 4 ). Figure 5 shows the changes of MLA, FFR CT distal to the scaffold and FFR CT scaffold gradient at 18 and 72 months.
Discussion
The present analysis represents the longest non-invasive imaging follow-up of patients treated with the Bioresorbable Everolimus- ). The patient with in-scaffold total occlusion is depicted with the red dot and patients with negative percentage area stenosis in green dots.
. . . . . . . . . . . Eluting Scaffold. In addition, for the first time a serial assessment of the functional component of a treated region is presented. The principal finding of this study is the durability of the initial angiographic results with a significant late lumen enlargement in the scaffolded region and the persistence of normalization of the FFR CT (Figures 6  and 7) . From 18 to 72 months after implantation a significant increase in the MSCT-derived mean and minimal luminal area was found. Late luminal gain has been observed in long-term follow-up of patients treated with bioresorbable scaffolds. With the first iteration of this device, evaluated in ABSORB Cohort A, after the early decrease in IVUS-derived MLAs, an increase in mean and minimal luminal areas was observed from 6 months to 2 years. This phenomenon was associated with a decrease in plaque area without changes in vessel area. In ABSORB Cohort B, a similar finding of increase in the IVUSderived mean luminal area with a decrease in plaque area was also demonstrated. The restoration of the natural integrity of the vessel, which responds to pulsatile flow (i.e. mechanotransduction) triggering atheroprotective signals (e.g. eNOS gene regulation, steady-levels of prostacyclin, etc.) in combination with drug elution might contribute to adapt the uncaged vessel to the physiologic stimuli. 17, 18 Moreover, late lumen enlargement might have a clinical impact. At the scaffolded region, the enlarged lumen increases blood flow and pressure and influence the haemodynamic microenvironment contributing, in some cases, to the normalization of the FFR CT and shear stress. Therefore, scaffolding in combination with optimal medical therapy (i.e. HMG-CoA reductase inhibitors and potentially PCSK9 inhibitors) has the potential to improve the durability of the results after PCI.
The interaction between the scaffold, its degradation process and the progression or regression of atherosclerosis is not yet fully understood. 19 In the present analysis, a non-significant reduction in mean plaque and vessel area was found. Nonetheless, a significant reduction in plaque burden was observed. Moreover, an increase in the calcified component of the plaque behind the scaffold depicted by an increase in the number of cross-sections with mixed plaque (calcified plus non-calcified plaques) and a parallel decrease in non-calcified plaque was found. It can be hypothesized that the presence of the drugeluting scaffold might play a role in plaque stabilization. However, the increase in the calcified component of the plaque could also be attributed to the natural history of the atherosclerotic process. Recently, adverse plaque characteristics (i.e. low attenuation plaque, positive remodelling and spotty calcification) have been shown to be associated with ischaemia. However, the interplay between plaque characteristics, endothelial function, and myocardial ischaemia requires further study.
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The strategy of plaque stabilization is currently being tested in the PREVENT (Preventive implantation of bioresorbable vascular scaffold on stenosis functional insignificant with signs of vulnerability) trial and in PROSPECT II & PROSPECT ABSORB (A multicentre prospective natural history study using multimodality imaging in patients with acute coronary syndromes combined with a randomized, controlled, intervention study) trial, which will further increase our knowledge of the impact of fully Bioresorbable Everolimus-Eluting Scaffold as an atherosclerosis stabilization strategy. 23, 24 The feasibility of the non-invasive FFR CT with the new software iteration was higher than in previous publications. 7 Furthermore, in six cases which had been previously rejected for FFR CT analysis at 18 months, re-assessment with the new software allowed for the computation of FFR CT . The software improvements in image segmentation and refinements in the construction of physiological models raised the acceptability of MSCT data for FFR CT analysis. In this study, for the first time, a serial FFR CT analysis after bioresorbable Everolimus-eluting scaffold implantation is presented. In 30 paired cases, there was no evidence of deterioration of the FFR CT between 18 months and 72 months. In addition, to specifically evaluate the device performance, the scaffold gradient was quantified (i.e. FFR CT distal-proximal to the scaffold). At 72 months, the scaffold gradient confirmed the persistence of the FFR CT normalization in the treated region with a delta scaffold gradient of 0 (IQR -0.018-0.010); 27 of 30 patients exhibited a delta scaffold gradient of < _ 0.05. In contrast to metallic stents, which hamper luminal assessment with MSCT due to the blooming effect, MSCT evaluation of the bioresorbable scaffold allows the identification of luminal contours providing a reliable angiographic assessment. 25 Additionally, due to the non-invasive nature of this evaluation, patients are more willing to undergo MSCT compared to standard invasive angiographic evaluation. In the overall ABSORB Cohort B, the attrition rate for invasive imaging follow-up was 50%. 4 For the long-term MSCT evaluation, 70% of the eligible patients were reconsented for a very late followup. This might have an implication for the design of future clinical trials with biodegradable scaffolds. Considering the high diagnostic accuracy, the incremental value of the functional evaluation, patient convenience and safety MSCT angiography with FFR CT offers a reliable alternative to invasive imaging and has the potential to become the method of choice for the follow-up of patients treated with bioresorbable scaffolds.
Limitations
This first-in-human trial included a non-complex population; therefore, these results should be confirmed in a larger and more complex population. Although the standard MSCT acquisition techniques were used, the scan protocol was adjusted for different CT scanners used at each institution and each follow-up which could have impacted vessel measurements. However, despite these limitations, this study used coronary MSCT in multiple patients and confirmed the occurrence of in-scaffold lumen enlargement. Even though FFR CT has demonstrated high diagnostic accuracy compared to invasive FFR, discrepancies between the in-scaffold MSCT-derived geometry and the true geometry might have an impact in the FFR CT results.
Conclusion
The long-term serial non-invasive MSCT with FFR CT assessment after bioresorbable scaffold implantation is feasible, with quantitative and functional diagnosis obtained in the vast majority of patients. The current series confirmed late lumen enlargement and continuance of normalization of the FFR CT .
Supplementary data
Supplementary data are available at European Heart Journal-Cardiovascular Imaging online. 
